Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$751.69K$751.69K+115.3% vs Q1 2025 Net Income-$3.18M-$3.18MN/M vs Q1 2025 EPS Diluted-$0.16-$0.16N/M vs Q1 2025 Operating Income-$4,072,535N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
Margins · derivedOperating margin-541.8%+878.4 pt vs Q1 2025
Net margin-423.0%+850.6 pt vs Q1 2025
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end